Epub 2014 Dec 26.Goodwin GM, Anderson I, Arango C, Bowden CL, Henry C, Mitchell PB, Nolen WA, Vieta E, Wittchen HU.Eur Neuropsychopharmacol. 2014 Dec;12(3):180-8. doi: 10.9758/cpn.2014.12.3.180. New medication classes are needed to improve treatment effectiveness in the depressed phase of bipolar disorder (BD). doi: 10.1136/bmjopen-2011-000643. Schematic of study design. Aspirin and minocycline may be efficacious adjunctive treatments for bipolar depression. Epub 2018 Jan 9. 2018 Jun;3(6):514-524. doi: 10.1016/j.bpsc.2017.12.011. These changes have been hypothesized to result from chronic inflammation, based partly on convergent evidence that proinflammatory cytokines are elevated in depressed patients with BD.
2020 Jan;25(1):131-147. doi: 10.1038/s41380-019-0414-4. Schematic of study design.
2012: Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomized, double-blind, placebo-controlled, 2×2 clinical trial. 2018 Jan 24;8(1):27. doi: 10.1038/s41398-017-0073-7.Husain MI, Chaudhry IB, Khoso AB, Husain MO, Hodsoll J, Ansari MA, Naqvi HA, Minhas FA, Carvalho AF, Meyer JH, Deakin B, Mulsant BH, Husain N, Young AH.Lancet Psychiatry. 2020 Jun;7(6):515-527. doi: 10.1016/S2215-0366(20)30138-3. You have reached the maximum number of saved studies (100).Please remove one or more studies before adding more.The purpose of this study is to determine whether minocycline and aspirin are effective in the treatment of depression in individuals with bipolar disorder.Minocycline 100mg PO BID for 6 weeks & Aspirin 81 mg PO BID for 6 weeksResponse to treatment defined as a >50% decrease in Montgomery-Asberg Depression Rating Scale scores for the final two consecutive visits.Remission defined as a score of <11 on Montgomery-Asberg Depression Rating Scale scores for the final two consecutive visits.Keywords provided by Laureate Institute for Brain Research, Inc.:Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): HighWire 2019 Oct;236(10):2909-2921. doi: 10.1007/s00213-019-5175-x. Free PMC article The principal aims of the proposed research is to evaluate the antidepressant efficacy in bipolar depression of minocycline, a drug with neuroprotective and immune-modulating properties, and of aspirin, at doses expected to selectively inhibit cyclooxygenase 1 (COX-1), within the context of a randomized, double-blind, placebo-controlled, parallel-group clinical trial following a 2 x 2 design.Specific Aims Specific Aim 1: To evaluate the efficacy of augmentation therapy with minocycline and/or aspirin for bipolar depression.The investigators will test the hypothesis that compared with placebo, participants receiving minocycline and/ or aspirin will show a greater treatment response rate (defined as a >50% increase on the MADRS for the final two consecutive visits).Specific Aim 2: To investigate the relationship between the response to minocycline, aspirin and markers of inflammation (serum concentrations of IL-6 and CRP).The investigators will test the hypotheses that: a) minocycline treatment will reduce inflammation to a greater extent than placebo; b) during minocycline treatment the change in inflammatory cytokine expression will correlate with the change in depression ratings; c) the baseline elevation of inflammatory markers will predict greater antidepressant response to minocycline.One hundred and twenty male or female outpatients between 18 and 65 years of age, who meet DSM-IV-TR criteria for BD (type I or II or NOS) and for a current major depressive episode will be recruited.
Given their potential import, additional studies …
Name must be less than 100 characters BMJ Open. (a) Illness onset after 40 years of age; (b) serious risk of suicide; (c) current delusions or hallucinations sufficient to interfere with the capacity to provide informed consent; (d) current manic symptoms of sufficient severity to pose a substantial risk of the development of a manic episode; (e) current treatment with more than four psychotropic medications; (f) medical illness including hepatic impairment, renal dysfunction, bleeding diatheses, cerebrovascular disease, hypertension or diabetes mellitus that is inadequately controlled by diet and/or medication, or known active peptic ulcer disease; (g) abuse of drugs or alcohol within the preceding 6 months, or substance dependence within the last year; (h) daily alcoholic beverage consumption equivalent to >3 oz.
2017 Aug;51(8):829-840. doi: 10.1177/0004867417709357. Unable to load your delegates due to an error Methods and analysis: 120 outpatients between 18 and 55 years of age, who meet DSM-IV-TR criteria for BD … Epub 2019 Apr 12.Psychopharmacology (Berl).
2018 Jul 2;9:697. doi: 10.3389/fphar.2018.00697. Furthermore, in another study, a minocycline adjunct allowed lower doses of antidepressants to be used, meaning that long-term adjunctive therapy may be a way to use lower doses of antidepressants and thereby reduce …